Literature DB >> 20859119

Caspr2 antibodies in patients with thymomas.

Angela Vincent1, Sarosh R Irani.   

Abstract

Myasthenia gravis is the best known autoimmune disease associated with thymomas, but other conditions can be found in patients with thymic tumors, including some that affect the central nervous system (CNS). We have become particularly interested in patients who have acquired neuromyotonia, the rare Morvan disease, or limbic encephalitis. Neuromyotonia mainly involves the peripheral nerves, Morvan disease affects both the peripheral nervous system and CNS, and limbic encephalitis is specific to the CNS. Many of these patients have voltage-gated potassium channel autoantibodies. All three conditions can be associated with thymomas and may respond to surgical removal of the underlying tumor together with immunotherapies and symptomatic treatments. Herein, we review the results of our recent studies that show that voltage-gated potassium channel autoantibodies are not principally directed against the potassium channels themselves but in some patients are directed against a protein that is complexed with potassium channels in both the peripheral nervous system and CNS, contactin-2 associated protein (Caspr2). These antibodies are common in the subgroup of patients with thymic malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20859119     DOI: 10.1097/JTO.0b013e3181f23f04

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  16 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Neuronal antibodies and paraneoplastic sensory neuropathy in thymoma.

Authors:  Anupama Barua; Paul Gozzard; Antonio E Martin-Ucar; Paul Maddison
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-05-22

Review 3.  Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex.

Authors:  M T Montojo; M Petit-Pedrol; F Graus; J Dalmau
Journal:  Neurologia       Date:  2014-01-30       Impact factor: 3.109

Review 4.  Immunity and Inflammation in Epilepsy.

Authors:  Annamaria Vezzani; Bethan Lang; Eleonora Aronica
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-18       Impact factor: 6.915

5.  Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.

Authors:  Estefanía Torres-Vega; Nuria Mancheño; Arantxa Cebrián-Silla; Vicente Herranz-Pérez; María J Chumillas; Germán Moris; Bastien Joubert; Jérôme Honnorat; Teresa Sevilla; Juan J Vílchez; Josep Dalmau; Francesc Graus; José Manuel García-Verdugo; Luis Bataller
Journal:  Neurology       Date:  2017-03-01       Impact factor: 9.910

Review 6.  Seizures and Epilepsies due to Channelopathies and Neurotransmitter Receptor Dysfunction: A Parallel between Genetic and Immune Aspects.

Authors:  Agustina M Lascano; Christian M Korff; Fabienne Picard
Journal:  Mol Syndromol       Date:  2016-07-22

7.  Treatment options in paraneoplastic disorders of the peripheral nervous system.

Authors:  Jean-Christophe Antoine; Jean-Philippe Camdessanché
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

Review 8.  Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes.

Authors:  Cheran Elangovan; Adeolu Morawo; Aiesha Ahmed
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.972

9.  Eyelid tremor in a patient with anti-caspr2 antibody-related encephalitis.

Authors:  Shuichi Ueno; Makito Hirano; Hikaru Sakamoto; Susumu Kusunoki; Yusaku Nakamura
Journal:  Case Rep Neurol       Date:  2014-08-27

Review 10.  Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases.

Authors:  Catherine Faivre-Sarrailh; Jérôme J Devaux
Journal:  Front Cell Neurosci       Date:  2013-10-29       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.